

CURRICULUM VITAE

JACQUELINE (JACKIE) BOSCH

jackie@ccc.mcmaster.ca

EDUCATIONAL BACKGROUND

- 2006 Enrolled PhD Program, School of Rehabilitation Science
McMaster University
- 1996 M.Sc. DME Program, McMaster University
Thesis: An Evaluation of the Reliability and Validity of the Canadian Occupational
Performance Measure
Supervisor: Mary Law Ph.D. O.T. (C), Assoc. Professor, School of Rehab. Sciences
- 1989 Bachelor of Science, Occupational Therapy
Queen's University

Other

- 2008 Sep What's new in stroke rehabilitation: 2nd National Stroke Rehabilitation Conference
Winnipeg, Canada
- 2008 May Innovations in Post-Stroke Rehabilitation: Clinical
Application of Movement Science Principles Hamilton, Canada
- 2008 Apr Pragmatic Randomized Clinical Trials Workshop Toronto, Canada
- 2008 Feb Central South Regional Stroke Clinical Rehabilitation
Forum Hamilton, Canada
- 2007 Sep 1st National Stroke Rehabilitation Conference Winnipeg, Canada
- 2007 Apr III Step: Regional Conference Philadelphia, USA
- 2006 Dec Research Methodology Course
McMaster University/ECLA Calafate, Argentina
- 2006 Sep European Association for the Study of Diabetes Copenhagen, Denmark
- 2005 Sep 10th International Symposium on Clinical Trials Oxford, UK
- 2005 Jul Fire Safety Training
Hamilton Gen Hosp Hamilton, Canada
- 2005 May Research Methodology Course: Co-sponsored by the Population Health
Research Institute, McMaster University and METsend
Istanbul, Turkey
- 2005 May Peace through Health Conference, McMaster University
Hamilton, Canada
- 2004 Jun Due Diligence, WHMIS Training
McMaster University Hamilton, Canada
- 2004 Apr WHMIS Training, McMaster University Hamilton, Canada
- 2003 Oct Canadian Cardiovascular Society Meeting Toronto, Canada
- 2003 Aug European Society of Cardiology Congress Vienna, Austria
- 2003 Apr Cardiovascular Disease Symposium Marbella, Spain
- 2003 Mar DataFax Users Group Workshop/Meeting Duck Key, USA
- 2003 Feb International Update on Cardiology Davos, Switzerland
- 2000 May Tri-Joint Congress (OT/PT/SP) Toronto, Canada
- 2000 Apr Society for Clinical Trials Toronto, Canada
- 2000 Feb DataFax Users Group Workshop/Meeting Whistler, Canada
- 1998 Jul World Federation of Occupational Therapists Conference
Montreal, Canada

1996 Jan	21st International Conference on Stroke and Cerebral Circulation American Heart Association	San Antonio, Texas
1995 Sep	Advanced Issues in the Design and Conduct of Randomized Clinical Trials Eighth International Symposium on Long-term Clinical Trials	Toronto, Canada
1995 Aug	XVIIth Congress of the European Society of Cardiology	Amsterdam, The Netherlands
1994 Oct	2nd International Cochrane Colloquium	Hamilton, Ontario
1994 Sep	XVIth Congress of the European Society of Cardiology	Berlin, Germany
1991 Nov	A Motor Relearning Approach to the Physical Treatment of Adult Hemiplegia	Toronto, Canada
1990 Apr	Postural Control and Movement Workshop	London, Ontario

EMPLOYMENT

Current Status at McMaster

Apr 2005 – Present	Associate Professor, School of Rehabilitation Science
2001 - Present	Project Manager, Population Health Research Institute
1999 – Apr 2005	Assistant Clinical Professor, School of Rehabilitation Science

Professional Associations

2001 - Present	College of Occupational Therapists of Ontario
1992 - Present	Ontario Society of Occupational Therapists
1989 - Present	Canadian Association of Occupational Therapists
1989 - Present	World Federation of Occupational Therapists

Employment History

Academic

1997 - 2001	Research Fellow, Population Health Research Institute
1996 - 1999	Clinical Lecturer School of Rehabilitation Science, McMaster University
1994	Tutorial Assistant Unit III: Adult Health and Physical Disability BHSc Occupational Therapy Program, McMaster University
1993-1997	Study Coordinator, Population Health Research Institute

Other (Clinical/Research)

2003	Clinical Research Associate Certificate Program: McMaster/Mohawk Sessional Lecturer
1993	Research Associate (protocol development, quality of life research) Workers Compensation Board Downsview, Ontario
1992-1993	Occupational Therapist Community Occupational Therapists & Associates (COTA), Toronto, Canada
1992-1993	Occupational Therapist Department of Veterans Affairs (contractual basis)
1990 - 1992	Occupational Therapist S.C. Cooper Sports Clinic, Mount Sinai Hospital Toronto, Ontario
1989 - 1991	Occupational Therapist (staff therapist) Mount Sinai Hospital Toronto, Ontario

SCHOLARLY AND PROFESSIONAL ACTIVITIES

Research Committees/Positions

1. Chronic Disease Prevention & Management (CDPM) Collaborative Steering Committee for the Hamilton Niagara Haldimand Brant LHIN, October 2008-present.
2. Health Related Successful Ageing Subcommittee, APOLLO study, Co-chair. September 2007 – present.
3. Reviewer, Canadian Journal of Occupational Therapy, September 2008.
4. Co-Chair Movement Science Workshop: May2/3 2008, McMaster University.
5. Steering Committee: Vascular events In noncardiac Surgery patlents cOhort evaluationN (VISION) Study (2007-current).
6. Selection Committee. HOPE Peace Through Health Chair. McMaster University. 2005-2006.
7. OT NOW CAPS (Critically Appraised PaperS) Advisory Group. 2005-present.
8. Hamilton Neurological Interest Group 2005-present.
9. Abstract Reviewer. Canadian Association of Occupational Therapists. 2002-2004.
10. Grant Reviewer. Canadian Occupational Therapy Foundation “Outcomes that Matter” competition. 1999.
11. Member of the OT Evidence-based practice research group. McMaster University.1997 to 2000.
12. Developed and implemented the Well Being Questionnaire as part of the SHARE (Study of Health Assessment and Risk in Ethnic groups) Study. 1996.

Academic Honours and Awards

- 2007 Contribution to the School Award, School of Rehabilitation Science, McMaster University
- 2001 President’s Award for Outstanding Service, Team Category, McMaster University
Awarded to Janice Pogue and myself for outstanding service with respect to the HOPE study
- 1989 Ontario Society of Occupational Therapists Book Prize
Highest mark on fourth year thesis

Courses Taught

- i) Undergraduate
- OT Programme, McMaster University
- 1999 Unit III: Occupation and Physical Health in Adulthood,
Clinical Skills Lab, OCCTHER 1L34, May-June, Course Co-coordinator
- 1998 Unit III: Occupation and Physical Health in Adulthood,
Clinical Skills Lab, OCCTHER 1L34, May-June, Course Co-coordinator
- 1997 Unit III: Occupation and Physical Health in Adulthood,
Clinical Skills Lab, OCCTHER 1L34, May-June, Course Co-coordinator
Resource Person, Term I
- 1996 Unit III: Occupation and Physical Health in Adulthood,
Clinical Skills Lab, OCCTHER 1L34, May-June, Course Co-coordinator
Resource Person, Term I
- ii) Graduate
- OT Programme, McMaster University
- 2008 Term 4: Applying Evidence to Practice: Integration, MSc(OT) 747, Sep-
Nov, Small Group Facilitator
- 2008 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator
- 2007 Term 4: Applying Evidence to Practice: Integration, MSc(OT) 747, Sep-
Nov, Small Group Facilitator

- 2007 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator
- 2007 Term 2: Person, Environment & Occupation, MSc(OT) 628, Professional
Roles & Experiential Practicum, Jan-Mar, Course Co-coordinator
- 2006 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator
- 2006 Term 2: Person, Environment & Occupation, MSc(OT) 628, Professional
Roles & Experiential Practicum, Jan-Mar, Course Co-coordinator
- 2005 Term 4: Applying Evidence to Practice: Integration, MSc(OT) 747, Sep-
Nov, Small Group Facilitator
- 2005 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator
- 2005 Term 2: Person, Environment & Occupation, MSc(OT) 628, Professional
Roles & Experiential Practicum, Jan-Mar, Course Co-coordinator
- 2004 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator
- 2004 Term 2: Person, Environment & Occupation, MSc(OT) 628, Professional
Roles & Experiential Practicum, Jan-Mar, Course Co-coordinator
- 2003 Term 4: Applying Evidence to Practice: Integration, MSc(OT) 747, Sep-
Nov, Small Group Facilitator
- 2003 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator
- 2003 Term 2: Person, Environment & Occupation, MSc(OT) 628, Professional
Roles & Experiential Practicum, Jan-Mar, Course Co-coordinator
- 2002 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator Clinical Skills Lab Unit III, Co-coordinator
- 2002 Term 2: Person, Environment & Occupation, MSc(OT) 628, Professional
Roles & Experiential Practicum, Jan-Mar, Course Co-coordinator
- 2001 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator Clinical Skills Lab Unit III, Co-coordinator
- 2000 Term 3: Disability, Development & Occupation, MSc(OT) 638
Professional Roles & Experiential Practicum, Apr-Jun, Course Co-
ordinator Clinical Skills Lab Unit III, Co-coordinator
- 2000 Term 3: Disability, Development & Occupation, MSc(OT) 637, Inquiry &
Integration, Guest Lecturer

Graduate Certificate/Online Masters Course, McMaster
University/University of British Columbia

- 2002 to present RHSC 504 Evaluating Sources of Evidence, Web Based Course,
Coordinator

Health Research Methodology (HRM) 730
Department of Clinical Epidemiology & Biostatistics
McMaster University

- 2006 Session: Data Management/Regulatory Issues
2007 Session: Data Management/Regulatory Issues
Problem Based Tutorial Leader
Session: Trial Organization, Administration & Finance
Problem Based Tutorial Leader
Evaluators of Final Assignment
2008 Session: Data Management/Regulatory Issues
Session: Trial Organization, Administration & Finance
- iii) Certificate
- 2003 HHSC – HTH04 Clinical Trials Methodology in Practice
Sessional Lecturer
- iv) Other:
- 2006 Research Methodology Course El Calafate, Argentina
ECLA, Universidad de la Frontera, Institute Dante Pazzanese de
Cardiologia & Population Health Research Institute McMaster
December 18-21
Lecturer: Overview of Study Intervention
Journal Club Facilitator: (Burnham *et al.*, 2006). Mortality after
the 2003 invasion of Iraq: A cross-sectional cluster sample
survey. *Lancet*, 368(9545), 1421-1428.
Problem Based Learning Facilitator
- 2005 Research Methodology Course Istanbul, Turkey
Metabolik Sendrom Derneği, METSEND &
Population Health Research Institute McMaster
May 29 - June 2
Lecturer: Session 1: Study Organization and Administration:
Single versus multicentre designs, Regulatory approval
Maximizing Adherence
Session 2: Study Organization and Administration:
Developing Case Report Forms, Setting up a database,
Ensuring data quality
Problem Based Learning Facilitator

Administrative Activities

- 2008-date Career progress/meti committee, School of Rehabilitation Science, McMaster University
- 2007- date Executive Committee, Population Health Research Institute, McMaster University
- 2007 –date Coordination Committee, Population Health Research Institute, McMaster University
- 2001-date Curriculum Committee, Occupational Therapy Program, McMaster University Member
- 2005-date Student Awards Committee, PHRI, McMaster University Member

Supervisorships

2007-2008 McMaster University Hamilton, Ontario
MSc OT 749, Evidence Based Practice Project
K. Ash, H. Hammond, S. Singh: Peace Through Health: An Interprofessional Elective

2006-2007 McMaster University Hamilton, Ontario
MSc OT 749, Evidence Based Practice Project
S. Archer, S. Brownrigg, A. Joseph, J. Zambon: Peace Through Health & the Role of Occupational Therapy

2005-2006 McMaster University Hamilton, Ontario
MSc OT 749, Evidence Based Practice Project
C. L. Bradley, K. Schnarr: Home based occupational therapy.

Mount Sinai Hospital Toronto, Ontario
2nd Year Clinical Placement - University of Toronto
1 student, May 1990 - June 1990, Completed

Mount Sinai Hospital, Toronto, Ontario
3rd Year Clinical Placement - University of Toronto
1 student, May 1991 - June 1991, Completed

LIFETIME FUNDING

Funding Agency: Ontario Stroke Strategy/Ministry of Health and Long-term Care
Amount: \$142,078
Funding Period: Jan 2009-Mar 2010
Dept where funds held: School of Rehabilitation Science, McMaster University
Project Title: Rehabilitation in the home environment: A knowledge transfer project to implement best practice and ensure continuity of care with stroke
Investigators: Principal: Richardson, J Co-Applicants: **Bosch J**, DePaul V, Jack S, Letts L, Moreland J, Wilkins S, Wishart L.

Funding Agency: Canadian Institutes of Health Research (CIHR)
Amount: \$37,724,042 (\$4,724,042 from CIHR)
Funding Period: Apr 2008 - Sep 2013
Dept where funds held: Population Health Research Institute, McMaster University
Project Title: HOPE-3: Heart Outcomes Prevention Evaluation -3
Investigators: Principal: Yusuf, S Co-Applicants: Lonn E, **Bosch J**, Pogue J, Dagenais G, Leiter L, Lamy A, Gafni A, McQueen M, Tobe S, Petrella R, Suskin N

Funding Agency: Program for Interprofessional Practice, Education and Research (PIPER), McMaster University
Amount: \$2,594.00
Funding Period: November 2007-June 2008
Dept where funds held: School of Rehabilitation Science
Project Title: Peace through Health: An Interprofessional Elective
Investigators: Principals: **Bosch, J**, Jung, B. Co-Applicants: The Peace Through Health Working Group

Funding Agency: Canadian Institutes of Health Research (CIHR)
Amount: \$5,345,774 (\$1,650,000 from CIHR)
Funding Period: April 2006 - March 2009
Dept where funds held: Population Health Research Institute, McMaster University
Project Title: EpiDREAM: Discovering environmental and genetic determinants of metabolic syndrome factors
Investigators: Principal: Anand S, Gaudet D, Co-Applicants: Gerstein H, Yusuf S, McQueen M, Pogue J, Keavney B, Perusse L, **Bosch J**

Funding Agency: Heart and Stroke Foundation of Canada
Amount: \$540,000
Funding Period: July 2006 – June 2009
Dept where funds held: Population Health Research Institute, McMaster University
Project Title: EpiDREAM – A prospective cohort study to determine environment and genetic determinants of metabolic syndrome related factors
Investigators: Principal: Anand S, Co-Applicants: Yusuf S, Gerstein H, **Bosch J**, Perusse L, Pogue J, Keavney B, Gaudet D, Merchant A

Funding Agency: Canadian Institutes of Health Research (CIHR)
Amount: \$1,744,000
Funding Period: Apr 2004 – Dec 2005
Dept where funds held: Clinical Epidemiology and Biostatistics (split with McGill, and Dalhousie)
Project Title: The Canadian Longitudinal Study of Aging: Developmental Activities - Phase I.
Investigators: Co-Principal: Wolfson C, Kirkland S, Raina P. Co-applicants include scientists across Canada, including **Bosch, J**.

Funding Agency: Ministry of Health and Long Term Care
Amount: \$249,446
Funding Period: September 2001- September 2002
Dept where funds held: McMaster University, School of Rehabilitation Science
Project Title: The HIPP Consultation and Rehabilitation Team: A client-centred, streamlined service strategy
Investigators: Baptiste S, Patterson C, Letts L, **Bosch J**, Richardson J, Edwards M, Stratford P, Law M, Harvey D, Anderson C, Mandy P.

Funding Agency: Canadian Institutes of Health Research
Amount: \$596,613
Funding Period: 2001-2005
Dept where funds held: Medicine
Project Title: Homocysteine Lowering and Atherosclerosis Reduction Trial
Investigators: Lonn, EM, Yusuf, S., Yi, Q, **Bosch J** et al.

Funding Agency: Canadian Occupational Therapy Foundation
Amount: \$35,000
Funding Period: 1999-2000
Dept where funds held: School of Rehabilitation Science
Project Title: Evidence-based occupational therapy
Investigators: Law M, Stewart D, **Bosch J**, Letts L, Philpot M, Pollock N, Westmorland M

Funding Agency: Canadian Occupational Therapy Foundation
Amount: \$9,985
Funding Period: 1997-1998
Dept where funds held: School of Rehabilitation Science
Project Title: Effective Occupational Therapy: Gathering, Analysing and Using the Evidence
Investigators: Law M, Pollock N, **Bosch J**, Letts L, Westmorland M, Philpot A

Funding Agency: Canadian Occupational Therapy Foundation
Amount: \$25,000
Funding Period: 1997
Dept where funds held: School of Rehabilitation Science
Project Title: Effective Occupational Therapy: Gathering, Analysing and Using the Evidence

Investigators: Law M, Pollock N, **Bosch J**, Letts L, Westmorland M, Philpot A.

LIFETIME PUBLICATIONS

Lifetime Count:

Peer reviewed publications:	
Articles:	41
Book chapters:	6
Non-peer reviewed articles:	6
Books:	1
Peer reviewed abstracts:	41

Peer-Reviewed Articles

1. Origin Trial Investigators. Writing Group: Gerstein H, Yusuf S, Riddle MC, Ryden L, **Bosch J**, Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). *American Heart Journal* 2008; 155(1); 26-32.
2. DREAM Trial Investigators. Writing Group: Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lon, E, McFarlane S, McQueen M, Teo K, Sheridan P, **Bosch J**, Pogue J, Yusuf S. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose. *Diabetes Care* 2008; 31(5): 1007-1014.
3. Yusuf S, **Bosch J**, Devereaux PJ, Collins R, Baigent C, Granger C, Califf R, Temple R. Sensible guidelines for the conduct of large randomized trials. *Clinical Trials* 2008;5: 38-39.
4. Duley L, Antman K, Arena J, Avezum A, Blumenthal M, **Bosch J**, Chrolavicius S, Li T, Ounpuu S, Perez AC, Sleight P, Svard R, Temple R, Tsouderous Y, Yunis C, Yusuf S. Specific barriers to the conduct of randomized trials. *Clin Trials* 2008;5: 40-48.

5. Gianni, M, **Bosch J**, Pogue J, Probstfield J, Dagenais G, Yusuf S, Lonn E (2007). Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. *European Heart Journal*, advance access March 29, 1-7.
6. Yusuf S, **Bosch J**. Independent design and conduct of clinical trials. *Clinical Trials*, 2006;3(6): 503-507.
7. Dream Trial Investigators. Writing Group: **Bosch, J.**, Yusuf, S., Gerstein, H. C., Pogue, J., Sheridan, P., et al. (2006a). Effect of ramipril on the incidence of diabetes. *New England Journal of Medicine*, 355(15), 1551-1562.
8. Dream Trial Investigators. Writing Group: Gerstein, H. C., Yusuf, S., **Bosch, J.**, Pogue, J., Sheridan, P., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. *Lancet*, 2006;368(9541): 1096-1105.
9. HOPE 2 Investigators, Writing Group: Lonn E, Held C, Arnold JMO, Probstfield J, McQueen MJ, Micks M, Pogue J, Sheridan P, **Bosch J**, Genest J, Yusuf S. Rationale, Design & Baseline Characteristics of a Large, Simple, Randomized Trial of Combined Folic Acid and Vitamins B6 & B12 in High-Risk Patients: The Heart Outcomes Prevention Evaluation (HOPE) - 2 Trial. *Canadian Journal of Cardiology*, 2005;22(1): 47-53.
10. Law, M, Majnemer A, McColl MA, **Bosch J**, Hanna S, Wilkins S, Birch S, Telford J, Stewart D. Home and community occupational therapy for children and youth: A before and after study. *CJOT*, 2005;72(5): 289-297.
11. HOPE and HOPE-TOO Investigators, Writing Group: **Bosch J**, Lonn EM, Pogue J, Arnold JM, Dagenais G, Yusuf S, on behalf of the. Long- Term Effects of Ramipril on Cardiovascular Events and on Diabetes: Results of the HOPE Study Extension. *Circulation*, 2005: 112; 1339-1346.
12. McQueen MJ, Lonn E, Gerstein HC, **Bosch J**, Yusuf S. The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences. *Scand J Clin Lab Inves*, 2005: 65(S240); 143-156.
13. Lonn EM, **Bosch J**, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais G, Yusuf S, on behalf of the HOPE-TOO Investigators. Effects of Long-Term Vitamin E Supplementation on Cardiovascular Events and Cancer: The HOPE Study Extension. *JAMA*, 2005: 293; 1338-47.
14. Mann JF, Yi Q, Sleight P, Dagenais G, H.C. Gerstein HC, Lonn E, **Bosch J**, Yusuf S on behalf of the HOPE Investigators. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. *Clin Nephrology*, 2005; 63: 181-187.
15. Dagenais GR, Yi Q, Mann JF, **Bosch J**, Pogue J, Yusuf S on behalf of the HOPE Investigators. Prognostic impact of total and abdominal obesity in women and men with cardiovascular disease. *American J Heart*, 2005: 149(1); 54-60.
16. Teo KK, Mitchell LB, Pogue J, **Bosch J**, Dagenais G, Yusuf S on behalf of the HOPE Investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. *Circulation* 2004: 110(11); 1413-7.
17. Gerstein HC, Yusuf S, Holman R, **Bosch J**, Pogue J on behalf of the DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple

- international trial of diabetes prevention: the DREAM trial. *Diabetologia*, 2004; 47(9):1519-27. Epub 2004 Aug 21.
18. Lonn E, Shaikholeslami R, Yi Q, **Bosch J**, Sullivan B, Tanser P, Magi A, Yusuf S. Effect of ramipril on left ventricular mass and function in normotensive high risk patients with preserved left ventricular ejection fraction: a substudy of the HOPE trial. *J Am Col Cardiol* 2004; 43; 2200-2206.
 19. Mann JFE, Lonn E, Yi Q, Gerstein HC, Hoogwerf B, Pogue J, **Bosch J**, Dagenais GR, Yusuf S, on behalf of the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Effects of vitamin E on cardiovascular outcomes in people with mild – moderate renal insufficiency: results of the HOPE study. *Kidney International*, 2004; 65(4); 1375-80.
 20. Ostergren J, Sleight P, Dagenais G, Danisa K, **Bosch J**, Qilong Y, Yusuf S. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. *Eur Heart J* 2004; 25; 17-24.
 21. Lonn E, Mathew J, Pogue J, Johnstone D, Danisa K, **Bosch J**, Baird MD M, Dagenais G, Sleight P, Yusuf S; On behalf of the Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. *J Cardio Risk* 2003; 10(6); 420-8.
 22. Mann JF, Yi QL, Sleight P, Dagenais GR, Probstfield J, Gerstein HC, Lonn EM, **Bosch J**, Yusuf S on behalf of the HOPE Investigators. New Trial Data On Prevention: Potassium and CV Risk in HOPE. *Pacing Clin Electrophysiology* 2003; 26; 1565.
 23. Arnold JM, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A, Lonn E, Pogue J, **Bosch J**; HOPE Investigators. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. *Circulation* 2003; 107(9); 1234-6.
 24. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, **Bosch J**, Dagenais G, Mann JF, Gerstein HC; HOPE Study.; MICRO-HOPE Study. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. *Diabetes Care* 2002; 25(11); 1919-27.
 25. Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, **Bosch J**, Suhan P, Micks M, Probstfield J, Bernstein V, Yusuf, S. Effect of long-term therapy with ramipril in high risk women. *JACC* 2002; 40(4); 693.
 26. Yusuf S, **Bosch J**. Urate levels as a predictor of cardiac deaths: causal relation or mere association? *Eur Heath J* 2002, 23(10), 760-1.
 27. **Bosch J**, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J. Use of ramipril in preventing stroke: double blind randomized trial. *BMJ* 2002, 324, 699-702.
 28. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, **Bosch J**, Sussex B, Probstfield J, Yusuf S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the Angiotensin Converting Enzyme Inhibitor Ramipril. *Circulation* 2001, 104, 1615-1621.

29. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, **Bosch J**, Wolffenbuttle BH, Zinman B. Ramipril and the development of diabetes. *JAMA* 2001, 286, 1882-5.
30. Dagenais GR, Yusuf S, Bourassa MG, **Bosch J**, Lonn EM, Kouz S, Grover J. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation study. *Circulation* 2001, 104, 522-6.
31. **Bosch, J.**, Yusuf, S., Pogue, J., Sleight, P., Lonn, E., Rangoonwala, B., Davies, R., Ostergren, J., Probstfield, J., on behalf of the HOPE Investigators. Evaluation of Ramipril, an Angiotensin Converting Enzyme Inhibitor, in Preventing Stroke in a Large Double Blind Randomised Trial. *BMJ*, 2002, 324, 699-704.
32. Mann JF, Gerstein HC, Pogue J, **Bosch J**, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. *Ann Intern Med.* 2001 Apr 17;134(8):707-9.
33. Lonn E, Yusuf S, Dzavik V, Doris IC, Yi Q, Smith S, Moore-Cox A, Derksen C, Magi A, **Bosch J**, Tartaglia C, Riley WA, Teo KK for the SECURE Investigators. Effects of ramipril and of vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and Vitamin E (SECURE). *Circulation*, 2001; 103: 919-925.
34. The Heart Outcomes Prevention Evaluation Study Investigators*. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High Risk Patients. *New England Journal of Medicine* 2000, 342(3), 145-153.
* writing group Yusuf S, Sleight P, Pogue J, **Bosch J**, Davies R, Dagenais G.
35. The Heart Outcomes Prevention Evaluation Study Investigators*. Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients. *New England Journal of Medicine* 2000, 342(3),154-161.
* writing group Yusuf S, Dagenais G, Pogue J, **Bosch J**, Sleight P.
36. The Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. *Lancet* 2000, 355(9200), 253-9.
37. Yusuf, S., Lonn, E., **Bosch, J.**, Gerstein, H. Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. *Clin and Exper Hypertension* 1999, Vol 21 (5&6), 835-845.
38. Anand SS, Yusuf S, Vuksan V, Devanesen S, Montague P, Kelemen L, **Bosch J**, Sigouin C, Teo KK, Lonn E, Gerstein HC, Hegele RA, McQueen M, for the SHARE Investigators. The study of health assessment and risk in ethnic groups (SHARE): rationale and design (1998). *Can J Cardiol* , Vol 14 (11), 1349-57.
39. Jha, P., Yusuf, S., Montague T., Dagenais G., Probstfield J., Sleight P., Richardson L., Johnstone D., Arnold M., Tsuyuki R., Davies R., Lonn E., **Bosch J.**, for the HOPE Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial on an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. *Can J Cardiol* 1996, Vol12 No.2, 127-137.
40. Gerstein H., **Bosch J.**, Pogue J., Taylor DW., Zinman B., Yusuf S. Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE-Inhibitor and Vitamin E in High Risk Patients with Diabetes: the MICRO-HOPE Study. *Diabetes Care* 1996, Vol19, No. 11, 1225-1228.

41. The Canadian Cardiovascular Collaboration. Collaborative cardiovascular trials in Canada. *Can J Cardiol* 1995, Vol 11, No. 8, 649-657.

Book Chapters

1. Letts L., **Bosch J.** (2005). In Measuring Outcomes: Measuring Occupational Performance in Basic Activities of Daily Living. M. Law, C. Baum, & Dunn, W (Eds.) *Measuring occupational performance Supporting Best Practice in Occupational Therapy, 2nd Ed.* Thorofare, NJ: Slack Inc.
2. Stewart, D., Law, M., Pollock, N., Letts, L., **Bosch, J.**, Westmorland, M. & Everett, A. (2002). In . Evidence-based rehabilitation: A guide to practice. Law, M (Ed.). *The effectiveness of cognitive- behavioural interventions with people with chronic pain: An example of a critical review of the literature.* Thorofare, NJ: Slack Inc.
3. Letts L, **Bosch J** (2001). In Measuring Outcomes: Measuring Occupational Performance in Basic Activities of Daily Living. M. Law, C. Baum, & Dunn, W (Eds.) *Assessing occupational performance* (pp. 121-159). Thorofare, NJ: Slack.
4. Lonn E, **Bosch J**, Flather M, Yusuf S on behalf of the Canadian Cardiovascular Collaboration. Vascular and anti-atherosclerotic effects of angiotensin converting enzyme inhibitors. Advanced issues in prevention and treatment of atherosclerosis. Euromed Communications, 1996. pp:63-82.
5. Lonn EM, Gerstein HC, **Bosch J**, Yusuf S: New approaches to prevention of atherosclerosis – an overview of Heart Outcome Prevention Evaluation study. In: New horizons in the management of post myocardial infarction patients. UK: Euromed communications Ltd; 1996. p. 39-55.
6. Jha P, Lonn E, Flather M, **Bosch J**, Yusuf S on behalf of the Canadian Cardiovascular Collaboration. Rationale for the HOPE (Heart Outcomes Prevention Evaluation) study. Unger T, Albrechts C, Ball SG (eds.) Ace inhibitors and high risk patients. Frankfurt : Euromed Communications on behalf of Hoechst Aktiengesellschaft, 1994. pp:89-103.

Non Peer-Reviewed Articles

1. Yusuf S., **Bosch J.** (1995). Cost effectiveness studies: Can benefit be shown only in high risk populations? *British Journal of Clinical Practice*, Suppl. 78, 22-25.
2. Jha, P., Lonn E., Flather M., **Bosch J.**, Yusuf S., on behalf of the Canadian Cardiovascular Collaboration: Rationale for the HOPE (Heart Outcomes Prevention Evaluation) study, in Unger T., Albrechts C, Ball SG, (eds) (1994). Ace Inhibitors and High Risk Patients. *Euromed Communications Lts. on behalf of Hoechst Aktiengesellschaft, Frankfurt*, 89 - 103.

Books and Monographs

1. Letts, L., Law, M., Pollock, N., Stewart, D., Westmorland, M., Philpot, A., & **Bosch, J.** (1999). A programme evaluation workbook for occupational therapists: An evidence-based practice tool. Ottawa, ON: CAOT Publications ACE.

Letters

1. Yusuf S, **Bosch J**, Sleight P. Preventing stroke with ramipril – author's reply. *BMJ* 2002; 326(7379): 52.

Technical Reports

1. Law, M., Stewart, D., Pollock, N., Letts, L, **Bosch, J.**, & Westmorland, M. (1998). Critical review form – Quantitative studies. Hamilton, ON: McMaster University. Retrieved Feb. 4, 2004 from: www.fhs.mcmaster.ca/rehab/ebp. Also in Law, M. (Ed.) (2002). Evidence-based Rehabilitation. A guide to practice. (pp. 306-308). Thorofare, NJ: Slack Inc.
2. Law, M., Stewart, D., Pollock, N., Letts, L, **Bosch, J.**, & Westmorland, M. (1998). Guidelines for critical review form – Quantitative studies. Hamilton, ON: McMaster University. Retrieved Feb. 4, 2004 from: www.fhs.mcmaster.ca/rehab/ebp. Also in Law, M. (Ed.) (2002). Evidence-based Rehabilitation. A guide to practice. (pp. 310-321). Thorofare, NJ: Slack Inc.
3. Law, M., Stewart, D., Letts, L, Pollock, N., **Bosch, J.**, & Westmorland, M. (1998). Critical review form – Qualitative studies. Hamilton, ON: McMaster University. Retrieved Feb. 4, 2004 from: www.fhs.mcmaster.ca/rehab/ebp. Also in Law, M. (Ed.) (2002). Evidence-based Rehabilitation. A guide to practice. (pp. 324-327). Thorofare, NJ: Slack Inc.
4. Law, M., Stewart, D., Pollock, N., Letts, L, **Bosch, J.**, & Westmorland, M. (1998). Guidelines for critical review form – Qualitative studies. Hamilton, ON: McMaster University. Retrieved Feb. 4, 2004 from: www.fhs.mcmaster.ca/rehab/ebp. Also in Law, M. (Ed.) (2002). Evidence-based Rehabilitation. A guide to practice. (pp. 330-338). Thorofare, NJ: Slack Inc.

PRESENTATIONS

Invited

1. **Bosch J.** Trial organization and administration. Trout-CANNeCTIN Workshop, Hamilton, Ontario. January 2009.
2. **Bosch J.** Is evidence based practice practical? The Future Starts Now. Rehabilitation/Seniors Program Staff Event, Hamilton Health Sciences. June 2008.
3. **Bosch J.** Summary of the 2007 Consensus Panel Recommendations. Movement Science Workshop, McMaster University. May 2008.
4. **Bosch, J.** Independent Conduct of Clinical Trials. 10th International Symposium on Clinical Trials, Oxford, England. September 2005.
5. **Bosch, J.** Role of the Renin-Angiotensin System in Preventing Cardiovascular Disease in High-Risk Patients. Workshop in the Cardiovascular Disease Symposium. Marbella, Spain. April 2003.
6. **Bosch J.** Role of the Renin-Angiotensin System in Cardiovascular Disease: Impact on Cerebrovascular Disease. International Update on Cardiology, Symposium sponsored by Aventis Pharma. Davos, Switzerland. February 2003.
7. **Bosch J.** Choice of Agents in the Prevention of Strokes. Canadian Cardiovascular Symposium, Satellite Symposium sponsored by Aventis Pharma. Edmonton, Alberta. October 2002.
8. **Bosch J.** Results of the HOPE Study. Neurological Consultants Meeting, Aventis Pharmaceuticals. New York, New York. January 2002.

9. **Bosch J.** Results of the HOPE Study. Swedish Practitioners Meeting sponsored by Aventis Sweden. Stockholm, Sweden. March 2001.
10. Letts, L., **Bosch, J.** "Program Evaluation Workshop". Full-day workshop sponsored by the Canadian Association of Occupational Therapists and the Occupational Therapy Evidence-Based Practice Research Group, McMaster University. November 2000.
11. **Bosch J.** The HOPE Project – A Canadian Success Story. Pharmaceuticals Sciences Group Conference, October 2000.
12. **Bosch J** on behalf of the HOPE Investigators. Impact of Ramipril on Prevention of Stroke. Consultants meeting organized by Aventis Canada, Netherlands, August 2000.
13. **Bosch J.** Clinical Research Associations and Clinical Research Co-ordinators – Optimizing Interactions. Workshop, Greater Toronto Area Community Cardiologists Organization, May 2000.
14. **Bosch J.** The HOPE Study Results. Ontario Medical Secretaries Association, May 2000.
15. **Bosch J** on behalf of the HOPE Investigators. The HOPE Study: Design and Baseline Characteristics, in the satellite symposium Emerging Approaches to Cardiovascular Disease: Detailed Results and Implications of the HOPE Study. Oral Presentation, American Heart Association, November 1999.
16. **Bosch J.** in the symposium Issues in Clinical Research: Good Clinical Practice. Oral Presentation, Manitoba Clinical Research Initiative, November 1999.
17. **Bosch J** on behalf of the HOPE Investigators. Design of HOPE Study and Key Results on Ramipril, in the satellite symposium Advances in Atherosclerosis Prevention at the Turn of the Millennium. Oral Presentation, Canadian Cardiovascular Society Meeting, October 1999.
18. **Bosch J** on behalf of the HOPE Investigators. The HOPE Study: design and baseline characteristics in the satellite symposium Detailed results and implications of the HOPE trial testing ramipril and vitamin E in high risk patients with cardiovascular disease and diabetes. Oral Presentation, European Society of Cardiology Meeting, August 1999.
19. **Bosch, J.,** Philpot, A., & Letts, L. "Cognitive behavioural approaches to chronic pain: A review of best practices". Telemedicine Canada, June, 1998.

Abstracts

1. Florez H, Gerstein H, Sheridan P, **Bosch J,** Goldberg R. Frailty grip is associated with glucose intolerance: Results from the Epidemiological Diabetes REductino Assessment with ramipril and rosiglitazone medication (Epi-DREAM) study population. Presented at the International Academy of Nutrition & Aging, August 2008. Albuquerque, New Mexico.
2. Anand S, Santarelli L, **Bosch J,** Budaj A, Lanas A, Avezum A, Shaw J, Marshall S, Probstfield J, Diaz R, Mohan V. Dagenais G, Yusuf S & Gerstein H. Glucose status predict CV events and death: The EpiDREAM multiethnic cohort. Presented at the American Heart Association November 2007.
3. Lonn E, Gerstein HC, **Bosch J,** G, Dagenais G, Diaz R, Sheridan P. Yusuf S, The STARR Investigators. Effects of ramipril and rosiglitazone on atherosclerosis: the Study of Atherosclerosis with Ramipril and Rosiglitazone (STARR). Presented at the American College of Cardiologists Conference 2007, Late-Breaking Clinical Trials I.

4. Gerstein, H.C., Yusuf, S., **Bosch, J.** Results of the DREAM Trial. 42nd Meeting of the European Association for the Study of Diabetes. September 14-17, 2006. Copenhagen, Denmark.
5. Gerstein, H.C., Yusuf, S., Holman, R., **Bosch, J.** Design and baseline characteristics of the DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial. *Diabetes* 2004; 53(Supp. 2): A483 (Abstract 2022-PO).
6. **Bosch J**, Lonn E, Pogue J, Micks M, Yusuf S on behalf of the HOPE and HOPE-TOO Investigators. Extended Follow-up of the ramipril component of the HOPE Study. Canadian Cardiovascular Society, October 26-29, 2003.
7. **Bosch J**, Lonn E, Pogue J, Micks M, Yusuf S on behalf of the HOPE and HOPE-TOO Investigators. Extended Follow-up of the ramipril component of the HOPE Study. European Society of Cardiology, August 30-September 3rd, 2003.
8. **Bosch J**, Pogue J, Probstfield J on behalf of the HOPE Investigators. Beneficial Effects of Ramipril on Cardiovascular Events in High Risk Patients Age 75 and Older: Secondary Outcomes from the HOPE Trial. American College of Cardiology Conference, March 2003.
9. Lonn E, Gerstein H, Pogue J, Yi Q, Byron J, Hoogwerf BJ, **Bosch J**, Dagenais G, Yusuf S. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients. 51st Annual Scientific Session of the American College of Cardiology, March 17-20, 2002, Atlanta. *J Am Coll Card* 2002; 39(5 Suppl A): 291A.
10. Lonn E, Roccaforte R, Yi Q, **Bosch J**, Probstfield J, Sleight P, Dagenais G, Yusuf S. Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial. 51st Annual Scientific Session of the American College of Cardiology, March 17-20, 2002, Atlanta. *J Am Coll Card* 2002; 39(5 Suppl A): 290A.
11. Dagenais GR, Auger P, Bogaty P, **Bosch J**, Gerstein H, Lonn E, Yi Q, Yusuf S for the HOPE Study Investigators. Impact of abdominal obesity on the occurrence of diabetes in subjects with ischemic cardiovascular disease. 74th Scientific Sessions of the American Heart Association, November 12-14, 2001, Anaheim, California. *Circulation* 2001; 107(Suppl II): II-833.
12. Dagenais GR, Yusuf S, Bourassa M, Yi Q, **Bosch J**, Lonn E, Kouz S, Grover J, on behalf of the HOPE Investigators. Effects of ramipril on coronary events in high-risk persons: results of the HOPE study. 54th Annual Meeting of the Canadian Cardiovascular Society, October 21-24, 2001, Halifax, Canada. *Can J Cardiology* 2001; 17(Suppl C): 183C.
13. Lonn EM, Shaishkoleslami R, Yi Q, **Bosch J**, Magi A, Yusuf S. Effects of Ramipril on left ventricular mass and function in normotensive, high-risk patients with normal ejection fraction. A substudy of HOPE. 50th Annual Scientific Session of the American College of Cardiology, March 18-21, 2001, Orlando, Fla. *J Am Coll Card* 2001; 37 (Suppl A): 165A.
14. Mann JF, Gerstein HC, Pogue JM, **Bosch J**, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and impact of ramipril: the HOPE study. 73rd Scientific Sessions of the American Heart Association, November 12-15, 2000, New Orleans, USA. *Circulation* 2000; 102(18): II-655.
15. Dagenais GR, Bourassa MG, Pogue JM, Yusuf S, **Bosch J.** Effects of ramipril on the incidence of myocardial infarction in high risk patients : the HOPE study. 73rd Scientific

- Sessions of the American Heart Association, November 12-15, 2000, New Orleans, USA. *Circulation* 2000; 102(18): II-705.
16. Dagenais GR, **Bosch J**, Kouz S, Pogue J, Yi Q, Yusuf S. Are waist-to-hip ratio and waist circumference predictors of cardiovascular mortality and myocardial infarction in high risk persons? 53rd Annual Meeting of the Canadian Cardiovascular Society, October 29-November 1, 2000, Vancouver, British Columbia. *Can J Cardiology* 2000; 16(Suppl F): 192F.
 17. **Bosch J**, Pogue J, Yusuf S on behalf of the HOPE Study investigators. Practical issues surrounding termination of a large international study: experience from the Heart Outcomes Prevention Evaluation (HOPE) Study. 21st Annual Meeting of the Society for Clinical Trials, April 16-19, 2000. Toronto, Canada. *Cont Clin Trials* 2000; 21(2S): 62S.
 18. Yusuf S, Arnold M, Mathew J, Young J, Avezum A, Bernstein V, **Bosch J**, Pogue J, Richardson L, Johnstone D on behalf of the HOPE (Heart Outcomes Prevention Evaluation) Investigators. Prevention of heart failure by Ramipril in high risk patients without heart failure or systolic dysfunction. 49th Annual Scientific Session of the American Congress of Cardiology, March 12-15, 2000. Anaheim (CA). *JACC* 2000; 35(2): 203A.
 19. **Bosch J**, Yusuf S, Pogue J, Probstfield J, Diaz R, Hoeschen R, Ostergren J on behalf of the HOPE Investigators. Impact of Ramipril and Vitamin E on cerebrovascular events in the HOPE (Heart Outcomes Prevention Evaluation) Trial. 49th Annual Scientific Session of the American Congress of Cardiology, March 12-15, 2000. Anaheim (CA). *JACC* 2000; 35(2 Suppl A): 324A.
 20. Dagenais GR, **Bosch J**, Pogue J, Yi C, Kouz S, Yusuf S, on behalf of the HOPE Investigators. Abdominal adiposity as a prognostic factor for persons at high risk of cardiovascular events. 49th Annual Scientific Session of the American Congress of Cardiology, March 12-15, 2000. Anaheim (CA). *JACC* 2000; 35(2 Suppl A): 284A
 21. Mathew J, Lonn E, Johnstone D, Probstfield J, Arnold M, Baird M, Danisa K, Habib N, **Bosch J**, Pogue J, Yusuf S on behalf of the HOPE Investigators. Left Ventricular Hypertrophy Predicts Death and Development of Heart Failure in High Risk Patients without Systolic Dysfunction, American College of Cardiology Scientific Session, March 2000.
 22. Gerstein HC, Mann JFE, Zinman B, **Bosch J**, Pogue J, Yusuf S, on behalf of the HOPE Study Investigators. Ramipril prevents cardiovascular events in high risk diabetic participants: results of the HOPE study. 49th Annual Scientific Session of the American Congress of Cardiology, March 12-15, 2000. Anaheim (CA). *JACC* 2000; 35(2 Suppl A): 301A
 23. Lonn E, Dzavik V, Doris I, Yi Q, Teo KK, **Bosch J**, Yusuf S, for the SECURE Investigators. Effects of ramipril and of vitamin E on atherosclerosis. 53rd Annual Meeting of the Canadian Cardiovascular Society, October 29-November 1, 2000, Vancouver, British Columbia. *Can J Cardiology* 2000; 16(Suppl F): 233F.
 24. Lonn E, McQueen M, Gerstein H, Dzavik V, Pogue J, **Bosch J**, Yusuf S, for the HOPE and SECURE Investigators. Effect of ramipril on glucose and insulin--results of the MORE-HOPE study. 53rd Annual Meeting of the Canadian Cardiovascular Society, October 29-November 1, 2000, Vancouver, British Columbia. *Can J Cardiology* 2000; 16(Suppl F): 233F.

25. Lonn E, Weitz J, Dzavik V, Crowther M, Pogue J, **Bosch J**, Yusuf S, for the SECURE and HOPE Investigators. Effects of ramipril and vitamin E on hematological markers of fibrinolysis, coagulation and endothelial function--results of the MORE-HOPE study. 53rd Annual Meeting of the Canadian Cardiovascular Society, October 29-November 1, 2000, Vancouver, British Columbia. *Can J Cardiology* 2000; 16(Suppl F): 233F.
26. Mathew J, Lonn E, Johnstone D, Probstfield J, Arnold M, Baird M, Danisa K, Habib N, **Bosch J**, Pogue J, Yusuf S, for the HOPE Investigators. Left ventricular hypertrophy predicts death and development of heart failure in high risk patients without left ventricular dysfunction. Submitted for *J Am Coll Cardiol* 2000; 35(Suppl A):212A.
27. Lonn EM, Dzavik V, Yusuf S, Smith S, Moore-Cox A, Derksen C, Magi A, Reynolds C, Musseau A, **Bosch J**, Pogue J, Doris I. Results of the study to evaluate carotid ultrasound changes in patients treated with Ramipril and Vitamin E (SECURE). American Heart Association 72nd Scientific Session. November 7-10, 1999. Atlanta (GA). *Circulation* 1999;100(18):1-185.
28. **Bosch J**, Letts L. Population Health: The Differing Perspectives and Their Applicability to Occupational Therapy. Roundtable Presentation, World Federation of Occupational Therapists Conference, July 1998.
29. Law, M., Pollock, N., Stewart, D., **Bosch, J.**, Letts, L., Philpot, A., & Westmorland, M. (1998). Effective occupational therapy: Gathering and analysing the evidence. Abstract summaries, World Federation of Occupational Therapists Congress.
30. Gerstein HC, Mann JF, Zinman B, **Bosch J**, Pogue JM, Joyce C, Dinneen S, Yusuf S. Albuminuria is highly prevalent and predicts cardiovascular events in high risk diabetic and nondiabetic patients. American Heart Association 70th Scientific Session, November 9-12, 1997, Orlando (Florida). *Circulation* 1997; 96(8 supp):I-225.
31. Sheth T, **Bosch J**, Chen J, Anand S, Nargundkar M, Nair C, Yusuf S. Ethnic differences in socioeconomic status and mortality. 50th annual meeting of the Canadian Cardiovascular Society, Winnipeg, Manitoba, October 5-9, 1997. *Can J of Card* 1997;13(Suppl C)89C.
32. **Bosch J**, Yusuf S, Taylor DW, Pogue J, for the HOPE Investigators. Use of fax in data management software in a multicentred, multinational trial: experience of the HOPE study. 2nd Joint Meeting of the Society for Clinical Trials and International Society for Clinical Biostatistics, Boston (Mass.), July 6-10, 1997. *Controlled Clinical Trials* 1997; 18:97S.
33. Lonn EM, **Bosch JJ**, Pogue JM, Dagenais G, Yusuf S. Left ventricular hypertrophy is a potent independent risk factor for adverse cardiovascular outcomes. *Circulation* 1997; 96(Suppl I):I-465.
34. Sheth T, **Bosch J**, Chen J, Anand S, Nargundkar M, Nair C, Yusuf S. Ethnic differences in socioeconomic status and mortality. 4th International Conference on Preventive Cardiology, Montreal, June 29-July 3, 1997. *Can J of Card* 1997;13(Suppl. B):156B.
35. Lonn EM, Pogue JM, **Bosch JJ**, Dagenais G, Yusuf S. Is there a gender bias in the cardiovascular drug treatment of high-risk women? *Circulation* 1997;96(Suppl I):I-27.
36. Lonn EM, Pogue J, **Bosch J**, Dagenais G, Yusuf S for the HOPE Investigators. Left ventricular hypertrophy is a potent independent risk factor for adverse cardiovascular outcomes. *Can J Cardiol* 1997;13(Suppl C): 106C.

37. Lonn EM, Pogue J, **Bosch J**, Dagenais G, Yusuf S for the HOPE Investigators. Is there a gender bias in the drug treatment of high-risk women and men? *Can J Cardiol* 1997; 13(Suppl C):119C.
38. **Bosch J**, Pais P, Pogue JM, Yusuf S. Why do individuals with higher socioeconomic status have lower risk of myocardial infarction? South Asian Cardiovascular Society, Oral Presentation, December, 1996.
39. **Bosch J**, Pais P, Pogue JM, Yusuf S. Why do individuals with higher socioeconomic status have lower risk of myocardial infarction? 49th Annual Meeting of the Canadian Cardiovascular Society. October 29-November 2, 1996, Montréal (Québec). *Can J Cardiol* 1996; 12(supp E):82E.
40. **Bosch J**, Law M. Reliability and Validity of the Canadian Occupational Performance Measure. Oral Presentation, Canadian Association of Occupational Therapists Conference, June 1996.
41. **Bosch J**, Yusuf S on behalf of the HOPE Investigators. HOPE Study. Poster Presentation, 21st International Joint Conference on Stroke and Cerebral Circulation of the AHA, Jan 1996.

Updated: January 20, 2009